How do immune checkpoint-targeted antibodies work? The need for improved pharmacokinetic evaluation in early phase studies
- PMID: 30307539
- DOI: 10.1093/annonc/mdy420
How do immune checkpoint-targeted antibodies work? The need for improved pharmacokinetic evaluation in early phase studies
Comment on
-
Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer.Ann Oncol. 2018 Nov 1;29(11):2208-2213. doi: 10.1093/annonc/mdy408. Ann Oncol. 2018. PMID: 30215677 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
